2025
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease
Walters M, Eapen M, Liu Y, El Rassi F, Waller E, Levine J, Strouse J, Antin J, Parikh S, Bakshi N, Dampier C, Jaroscak J, Bergmann S, Wong T, Kota V, Pace B, Lekakis L, Lulla P, Nickel R, Kasow K, Popat U, Smith W, Yu L, DiFronzo N, Geller N, Kamani N, Klings E, Hassell K, Mendizabal A, Sullivan K, Neuberg D, Krishnamurti L. Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease. Blood Advances 2025, 9: 955-965. PMID: 39471440, PMCID: PMC11907447, DOI: 10.1182/bloodadvances.2024013926.Peer-Reviewed Original ResearchHematopoietic cell transplantationVaso-occlusive painStandard of careSickle cell diseaseCell transplantationCell diseaseSCD-related eventsHLA-matched siblingTransplant-related mortalityPeriod of follow-upSurvival 2 yearsIntent-to-treat principleComparison of survivalDisease-modifying therapiesDisease-related mortalityUnrelated donorPrimary endpointCurative potentialTreatment armsDonor searchFollow-upCompare outcomesEligibility confirmationFunctional outcomesSecondary outcomes
2022
Oropharyngeal Carcinoma
Husain Z, Kang J, Lee N, Poon I. Oropharyngeal Carcinoma. Practical Guides In Radiation Oncology 2022, 15-25. DOI: 10.1007/978-3-030-99590-4_2.Peer-Reviewed Original ResearchLong-term treatment toxicityOropharyngeal squamous cell carcinomaCurative treatment optionSquamous cell carcinomaPatterns of failureElective coverageOropharyngeal carcinomaTreatment toxicityNeck malignanciesAccurate target delineationCell carcinomaDisease stageTreatment optionsCurative potentialPhysical examCommon headClinical scenariosRadiation oncologistsSurgical anatomyTarget volumeTarget delineationVolume coverageCarcinomaMultimodal imagingPrimary targetTranslational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma
Cadamuro M, Romanzi A, Guido M, Sarcognato S, Cillo U, Gringeri E, Zanus G, Strazzabosco M, Simioni P, Villa E, Fabris L. Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma. Journal Of Personalized Medicine 2022, 12: 1086. PMID: 35887583, PMCID: PMC9324584, DOI: 10.3390/jpm12071086.Peer-Reviewed Original ResearchTumor-associated lymphangiogenesisTumor-draining lymph nodesTargetable genetic alterationsNovel therapeutic targetCholangiocarcinoma invasivenessLiver transplantationLiver resectionLymph nodesCurative potentialPrimary tumorAvailable treatmentsSurgical proceduresLymphatic metastasisTherapeutic targetTumor microenvironmentTranslational valueMolecular profilingGenetic alterationsLymphangiogenesisCholangiocarcinomaMetastasisProgressionCurrent knowledgeRecent findingsMolecular mechanisms
2020
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve
Vining C, Izquierdo F, Eng O, Turaga K. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve. Journal Of Surgical Oncology 2020, 122: 85-95. PMID: 32436240, DOI: 10.1002/jso.25939.Peer-Reviewed Original ResearchTransplant Physicians’ Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool
Mishra A, Preussler J, Al-Mansour Z, Bachanova V, Bhatt V, Bredeson C, Chhabra S, D'Souza A, Dahi P, DeFilipp Z, Gowda L, Hacker E, Hashmi S, Howard D, Jakubowski A, Jayani R, Johnston L, Koll T, Lin R, McCurdy S, Michaelis L, Muffly L, Nathwani N, Olin R, Popat U, Rodriguez C, Rosko A, Runaas L, Sabloff M, Shore T, Shune L, Sorror M, Sung A, Ustun C, Wood W, Burns L, Artz A. Transplant Physicians’ Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. Transplantation And Cellular Therapy 2020, 26: s45-s46. DOI: 10.1016/j.bbmt.2019.12.115.Peer-Reviewed Original ResearchHematopoietic cell transplantationKarnofsky performance scoreTransplant physiciansUpper age limitAllogeneic hematopoietic cell transplantationGeriatric assessment toolsNon-myeloablative conditioningMarrow Transplant ResearchOnline cross-sectional surveyHealth assessment toolMajority of centersClinical support staffCross-sectional surveyAssessment toolAdult physiciansMyeloablative regimenOlder ptsRegimen intensityConditioning regimensOlder patientsSupportive careInternational BloodRisk stratificationCell transplantationCurative potential
2019
Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood
Eissa MAL, Lerner L, Abdelfatah E, Shankar N, Canner JK, Hasan NM, Yaghoobi V, Huang B, Kerner Z, Takaesu F, Wolfgang C, Kwak R, Ruiz M, Tam M, Pisanic TR, Iacobuzio-Donahue CA, Hruban RH, He J, Wang TH, Wood LD, Sharma A, Ahuja N. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clinical Epigenetics 2019, 11: 59. PMID: 30953539, PMCID: PMC6451253, DOI: 10.1186/s13148-019-0650-0.Peer-Reviewed Original ResearchConceptsStage IIB diseasePancreatic cancerIIB diseaseStage IIACA 19Stage IBiomarker panelBlood-based biomarker panelPre-operative CA 19Stage I patientsCell-free tumor DNAHigh-risk populationPotential blood biomarkersMost pancreatic cancersBackgroundDespite improvementsCurative resectionSurgical resectionI patientsTwo-gene panelPancreas cancerBlood biomarkersCurative potentialCancer managementAdvanced stageCombination panelGlycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target
Martin DT, Shen H, Steinbach-Rankins JM, Zhu X, Johnson KK, Syed J, Saltzman WM, Weiss RM. Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target. Molecular Cancer Therapeutics 2019, 18: molcanther.1079.2017. PMID: 30381445, PMCID: PMC6363894, DOI: 10.1158/1535-7163.mct-17-1079.Peer-Reviewed Original ResearchConceptsBladder cancer cell linesBladder tumorsBladder cancerCancer cell linesHigh-grade bladder cancer cell linesCancer xenograft mouse modelBladder cancer growthAggressive bladder cancerPotential therapeutic targetHuman bladder tumorsXenograft mouse modelBladder cancer progressionCell linesBladder tumor cellsCurative potentialOptimal treatmentTumor gradePatient outcomesReduced cell migrationTumor volumeTumor categoryMouse modelTherapeutic targetTumor aggressivenessCancer growth
2013
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity
Ghosh A, Dogan Y, Moroz M, Holland A, Yim N, Rao U, Young L, Tannenbaum D, Masih D, Velardi E, Tsai J, Jenq R, Penack O, Hanash A, Smith O, Piersanti K, Lezcano C, Murphy G, Liu C, Palomba M, Sauer M, Sadelain M, Ponomarev V, van den Brink M. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. Journal Of Clinical Investigation 2013, 123: 2654-2662. PMID: 23676461, PMCID: PMC3668849, DOI: 10.1172/jci66301.Peer-Reviewed Original ResearchMeSH KeywordsAdoptive TransferAnimalsAntigen-Presenting CellsCell Line, TumorCytotoxicity, ImmunologicGraft RejectionGraft vs Host DiseaseHEK293 CellsHumansImmunotherapy, AdoptiveLeukemia, Lymphocytic, Chronic, B-CellMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasm TransplantationT-LymphocytesTNF-Related Apoptosis-Inducing LigandConceptsGVT responseT cellsAllo-HSCTAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationCellular therapyAbsence of GVHDDR5-dependent mannerDonor T cellsAlloreactive T cellsStem cell transplantationChronic lymphocytic leukemia cellsPrecursor T cellsThird-party donorsLymphocytic leukemia cellsApoptosis-inducing ligandGVT activityHost diseaseCell transplantationCurative potentialTumor responseGVHDCertain malignanciesMouse modelHuman leukemia cell lines
1992
Pharmacology of agents used in bone marrow transplant conditioning regimens
Wiebe V, Smith B, DeGregorio M, Rappeport J. Pharmacology of agents used in bone marrow transplant conditioning regimens. Critical Reviews In Oncology/Hematology 1992, 13: 241-270. PMID: 1476655, DOI: 10.1016/1040-8428(92)90092-5.Peer-Reviewed Original ResearchConceptsBone marrow transplantationTotal body irradiationConditioning regimensPharmacology of agentsSingle fraction total body irradiationTransplant conditioning regimensTransplantation conditioning regimensConditioning regimentEffective immunosuppressionTBI regimensBody irradiationMarrow transplantationCurative potentialEngraftment rateDonor histocompatibilityToxicity profilePharmacologic behaviorRegimensAntineoplastic propertiesHematopoietic spaceAntineoplastic activityDisease statesPharmacology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply